Improving Clinical Trial Efficiency: Centralized and Risk-Based Monitoring

The problem: Monitoring clinical trial data using SDV

With clinical trials becoming increasingly complex over the past decades, the 

On-site review of clinical trial documents, classically taking the form of source data verification (SDV), together with investigator site management, represent a 

. A major drawback of indiscriminately applying exhaustive (100%) SDV is that it is costly and time-intensive.

Although SDV in clinical trials has often been considered standard protocol, it has also been shown to have limitations in terms of identifying and correcting issues. Especially with recent developments in clinical trial monitoring solutions, many of which include alternative data validation tools, SDV is now considered by some to be unnecessary at best, and wasteful at worst – particularly for studies or parts of studies wherein the data is already of high quality or when minor issues would not be detrimental to the study results nor patient safety. Complete SDV was also shown to be 

Solution: Centralized and risk based monitoring (RBM)

It is becoming widely accepted that the limited resources in a clinical trial would be better spent by focusing solely on vital tasks, which explains the rise of centralized monitoring and risk-based monitoring (RBM).

In centralized and risk-based monitoring approaches, monitoring tasks are prioritized according to the relative risks and severity of potential consequences in the various aspects of clinical trial operations. Monitoring is conducted in a coordinated manner, from centralized locations, according to the highest risk areas.

If problems or potential issues are identified, then site-specific or more thorough investigations can be conducted. This prevents the spending of limited resources on indiscriminate monitoring of data or operations where the potential benefit (and potential risk) is minimal or even null.

Numerous major regulatory bodies, including the FDA, have formally recognized and put forth 

 for centralized and risk-based monitoring as effective strategies for monitoring clinical trial data.

In this article, we will further define centralized monitoring and risk-based monitoring (which often overlap or are combined into one approach), explore their advantages and drawbacks in comparison to traditional monitoring methods including SDV, and go over some considerations for transitioning smoothly to a centralized RBM strategy. At the end of the article, we include links to 3 trusted RBM providers.

Centralized monitoring describes the tracking and assessment of clinical trial operations and data by dedicated staff (who may be trial monitors, investigators, statisticians) at locations separate from the clinical trial sites.

This lies in contrast to on-site monitoring, where separate clinical trial monitors may visit trial sites in-person to monitor operations and validate data, which necessitates more personnel, more travel time and logistical considerations, and more complex oversight. In centralized monitoring, monitoring is coordinated and executed from a centralized location in order to streamline monitoring operations and optimize resource allocation, and is usually assisted by technological solutions integrating the various trial sites. Nonetheless, on-site monitoring may still be needed to further investigate specific instances or high-risk aspects, so the two approaches are not mutually exclusive.

Centralized monitoring enables the possibility of performing statistical analysis to identify trends, both within and between trial sites, and thus is useful for assessing the performance of different trial sites and identifying potential issues such as data outliers or improperly functioning equipment (indicated by unexpected values) and noncompliance.

Risk-based monitoring, or RBM, refers to the concept of identifying the principal risk areas in a clinical trial, and prioritizing the monitoring of these aspects to assess and mitigate issues that could cause problems in terms of the safety and/or the quality of the trial. It can also be thought of as a method of centralized monitoring based on a risk-based approach.

Risk-based monitoring aims to make the monitoring process more efficient and aligned with the goal of ensuring the safety and quality of the study by using statistical indicators and thresholds to quickly identify errors where they are most likely to occur and/or have relevant consequences.

The design of a risk-based monitoring approach requires 3 steps:

1. Identify which operations and data are most critical to the trial

, in terms of patient safety, regulatory affairs, and trial quality. Designate these factors as the indicators which will be monitored in the central dashboard.

 to predict the potential risk posed by the main potential sources of error in the study. Establish thresholds which would indicate the severity of risk represented by different values, which will enable you to set up a “traffic-light” system or other visually obvious cues for alerting the monitor to any potential issues.

 based on these risk areas, indicators, and thresholds, which should include details and clear instructions on the monitoring methods, clarify who is responsible for which aspects of monitoring and responding to issues, and how risks and errors will be communicated between the various actors involved.

RBM and its relation to Risk Based Quality Management (RBQM)

RBM is closely related to another concept, risk-based quality management (RBQM), which is a broader clinical trial quality management framework that was 

“the identification of the risks on a continuous basis for risk-bearing activities throughout the design, conduct, evaluation and reporting of clinical trials.”

 Risk-based monitoring focuses on data, using statistical approaches and software, to determine potential risk to trial safety or quality and encourage rational decision-making by enabling sponsors and investigators to recognize and address issues as they emerge. Such an approach can allow investigators to save costs, optimize data quality and integrity, and ensure patient safety. RBQM, in a broader sense, refers to a quality management system that governs the entire clinical trial through a risk-based focus. ICH 

 (GCP) guidelines from 2016 suggest the application of a risk-based approach to all aspects of clinical trial quality management systems.

What are the benefits and drawbacks of risk based monitoring?

Risk-based monitoring offers several advantages for clinical trials; let's take a look at the main benefits in more detail.

Although risk-based monitoring strategies offer several advantages, there are also certain drawbacks associated with the transition to such a strategy.

How do you implement risk based monitoring?

Numerous organizations have provided guidance and considerations for designing and implementing a risk-based monitoring strategy, including the 

. You can find the initial design of an RBM strategy in an earlier section of this article under the heading “Risk-Based Monitoring”. After the trial begins, implementation of the monitoring strategy generally involves the following aspects:

If you are intrigued and curious about ready-to-use RBM solutions, here are some trusted RBM vendors to get you started on your search for a partner:

Centralized and risk-based monitoring approaches are becoming increasingly recognized as effective methods for monitoring clinical studies, with major regulatory bodies such as the FDA and EMA already having stated their approval and publishing guidelines for adopting such strategies. As compared to traditional alternatives like exhaustive SDV and pure on-site monitoring, centralized RBM can streamline monitoring operations and maximize resource efficiency, enable rapid detection of errors, enhance participant safety, and improve trial data quality. Sponsors have the option of contracting a partner to undertake the monitoring or developing their own tools and methods for integrating such an approach into their operations.

Other Trials to Consider

Enhanced Spatial Targeting in ECT Utilizing FEAST

Suvorexant

G2SCID vector

Azacitidine

Leucoselect Phytosome

PACT

Lutetium-177 Octreotate

Niraparib

Belzutifan

Standard surveillance

Popular Categories

Glaucoma Clinical Trials in Glendale, AZ

Glaucoma Clinical Trials in Los Angeles, CA

Lung Cancer Clinical Trials in Glendale, AZ

Lung Cancer Clinical Trials in Los Angeles, CA

Popular Guides

Learn More About These Treatments

Minirin

Limbitrol Ds

Clindamycin Phosphate And Benzoyl Peroxide

Felbatol

Phrenilin Forte

Winlevi

Reserpine

Rexulti

Nifedipine

Flexeril